A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

NCT00570635 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms

Interventions

DRUG: XL820
DRUG: XL820

Sponsor

Exelixis